New York, July 08, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "RNA Interference Technology Market Research Report by Type, Therapeutics, Application, Region - Global ...

Nanoparticles that deliver short strands of RNA offer a way to treat cancer and other diseases by shutting off malfunctioning genes. Although this approach has shown some promise, scientists are still ...

According to the report, the global RNA based therapeutics industry was estimated at $4.93 billion in 2021, and is anticipated to hit $25.12 billion by 2030, registering a CAGR of 17.6% from 2021 to ...

GlaxoSmithKline has entered into a pact potentially worth over $700 million with privately-owned Danish firm Santaris Pharma to develop antivirals using the latter’s RNA-interference technology.

In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article ...

Under the collaboration, Boehringer Ingelheim and Ribo will develop RNA-based therapeutics to treat NASH/MASH. On Jan. 3, 2024, Boehringer Ingelheim announced that it has entered into a multi-target ...

(Reuters) -Swiss drugmaker Novartis has signed an up to $5.2 billion licensing and options deal with Argo Biopharmaceutical for its experimental candidates that target cardiovascular diseases, the ...